Perceptive Advisors’s Epizyme, Inc EPZM Stock Holding History

Perceptive Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,165	Closed	-$20K	–	170
2017 Q1	$20K	Buy	+1,165	New	+$15.5K	﹤0.01%	144
2015 Q3	–	Sell	-60,000	Closed	-$1.44M	–	193
2015 Q2	$1.44M	Buy	+60,000	New	+$1.15M	0.09%	110
2015 Q1	–	Sell	-432,619	Closed	-$8.16M	–	185
2014 Q4	$8.16M	Buy	432,619 +148,729	+52%	+$3.47M	0.68%	37
2014 Q3	$7.7M	Buy	283,890 +241,288	+566%	+$7.5M	0.78%	34
2014 Q2	$1.33M	Sell	42,602 -10,000	-19%	-$235K	0.13%	75
2014 Q1	$1.2M	Buy	+52,602	New	+$1.59M	0.13%	87
2013 Q3	–	Sell	-18,000	Closed	-$506K	–	123
2013 Q2	$506K	Buy	+18,000	New	+$462K	0.05%	67

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Perceptive Advisors's EPZM Position: Q2 2017 in Review

Perceptive Advisors sold out of Epizyme, Inc (EPZM) in Q2 2017, closing a stake of 1,165 shares — an estimated $20K sold.

Perceptive Advisors first reported a position in EPZM in Q2 2013 and held it in 7 quarters. The position peaked at $8.16M in Q4 2014. 108 funds tracked by Wall St. Rank hold EPZM as of Q2 2017.

Perceptive Advisors reported no remaining Epizyme, Inc position as of Q2 2017 after selling out during the quarter.
Perceptive Advisors sold 1,165 Epizyme, Inc shares in Q2 2017, an estimated $20K.
Perceptive Advisors first reported a position in Epizyme, Inc in Q2 2013 and held it in 7 quarters.
Perceptive Advisors's Epizyme, Inc position peaked at $8.16M in Q4 2014.
108 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.